Holen Sie sich die Stockscreener-App
57.24
2.45%
1.37
Handel nachbörslich:
56.18
-1.06
-1.85%
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality - finance.biggo.com
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance
Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? - Yahoo Finance
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Handelsbanken Fonder AB - marketbeat.com
(IONS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing Growth Potential with a 57.94% Upside - DirectorsTalk Interviews
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
3 Healthcare Stocks Retail Investors May Recheck After The July Jobs Shock - Sahm
Ionis Pharmaceuticals Inc. R (ISI.DU) Q1 FY2026 earnings call transcript - finance.yahoo.com
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP - marketbeat.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock forecasts - Yahoo Finance UK
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals - simplywall.st
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 72% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - marketbeat.com
Perceptive Advisors LLC Makes New $37.84 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Forecasts - Yahoo Finance
Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key Catalysts Approach - Morningstar
Ionis Pharmaceuticals (NASDAQ:IONS) Lowered to "Sell" Rating by Wall Street Zen - marketbeat.com
IONS5835891 Bond Profile — Key Metrics - TradingView
Ionis Pharmaceuticals (NASDAQ:IONS) Director Michael Hayden Buys 5,000 Shares - marketbeat.com
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook - TradingView
Ionis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ionis Pharmaceuticals: Q2 Earnings Snapshot - Barchart.com
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire - Yahoo Finance
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS - GlobeNewswire
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewi - The National Law Review
Ionis earnings ahead: Tryngolza launch in focus amid rivalry By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review
Ionis Pharmaceuticals Inc (IONS) Cash Flow - TradingKey
Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews
Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc. (IONS) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Sells 239,269 Shares of Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by KBC Group NV - marketbeat.com
Ionis Pharmaceuticals Inc (IONS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ionis Pharmaceuticals Inc (IONS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ionis Pharmaceuticals Inc (IONS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ionis Pharmaceuticals Inc (IONS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ionis Pharmaceuticals Inc. (IONS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
IONS|Ionis Pharmaceuticals Inc|Price:56.550|Chg%:+0.680 - TradingKey
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by California Public Employees Retirement System - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story - Yahoo Finance
Ionis stock trades steady as genetic medicine pipeline advances and revenue grows - Ad-hoc-news.de
Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh? - Yahoo Finance
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23%HBSS - Morningstar
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Canaccord reiterates Ionis stock rating on Tryngolza advantage By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):